{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:32:07Z","timestamp":1762867927490,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11255-019-02272-5","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:03:17Z","timestamp":1568746997000},"page":"2295-2304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients"],"prefix":"10.1007","volume":"51","author":[{"given":"Hanzada Mohamed El","family":"Maghrabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Yahia","family":"Elmowafy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman Fathi","family":"Refaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Adel","family":"Elbasiony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal Elsayed","family":"Shiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-7286","authenticated-orcid":false,"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Adel","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"2272_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1525-139X.2005.18108.x","volume":"18","author":"L Finelli","year":"2005","unstructured":"Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ (2005) National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18:52\u201361","journal-title":"Semin Dial"},{"key":"2272_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/HMER.S113681","volume":"9","author":"A Gomaa","year":"2017","unstructured":"Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I (2017) Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 9:17\u201325","journal-title":"Hepat Med"},{"key":"2272_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/01.tp.0000179637.37276.5a","volume":"80","author":"MA Schnitzler","year":"2005","unstructured":"Schnitzler MA, Lentine KL, Burroughs TE (2005) The cost effectiveness of deceased organ donation. Transplantation 80:1636\u20131637","journal-title":"Transplantation"},{"key":"2272_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1432-2277.2009.00926.x","volume":"22","author":"B Dom\u00ednguez-Gil","year":"2009","unstructured":"Dom\u00ednguez-Gil B, Morales JM (2009) Transplantation in the patient with hepatitis C. Transpl Int 22:1117\u20131131","journal-title":"Transpl Int"},{"key":"2272_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2008.81","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2008","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2008) KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109:S1\u2013S99. \nhttps:\/\/doi.org\/10.1038\/ki.2008.81","journal-title":"Kidney Int Suppl"},{"key":"2272_CR6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ki.2014.50","volume":"85","author":"F Fabrizi","year":"2014","unstructured":"Fabrizi F, Messa P, Martin P (2014) Update to hepatitis C review. Kidney Int 85:1238\u20131239","journal-title":"Kidney Int"},{"key":"2272_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","volume":"90","author":"DR Scott","year":"2010","unstructured":"Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, Levy MT (2010) Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 90:1165\u20131171","journal-title":"Transplantation"},{"key":"2272_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.transproceed.2009.01.074","volume":"41","author":"L Santos","year":"2009","unstructured":"Santos L, Alves R, Macario F, Parada B, Campos M, Mota A (2009) Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience. Transplant Proc 41:880\u2013882","journal-title":"Transplant Proc"},{"key":"2272_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature04083","volume":"436","author":"RS Brown","year":"2005","unstructured":"Brown RS (2005) Hepatitis C and liver transplantation. Nature 436:973\u2013978","journal-title":"Nature"},{"key":"2272_CR10","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1111\/ajt.12835","volume":"14","author":"S Baid-Agrawal","year":"2014","unstructured":"Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M (2014) Hepatitis C virus infection and kidney transplantation in 2014: what\u2019s new? Am J Transplant 14:2206\u20132220","journal-title":"Am J Transplant"},{"key":"2272_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","volume":"49","author":"M Berenguer","year":"2008","unstructured":"Berenguer M (2008) Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49:274\u2013287","journal-title":"J Hepatol"},{"key":"2272_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2016.09.046","volume":"91","author":"A Blanchard","year":"2017","unstructured":"Blanchard A, Bockenhauer D, Bolignano D, Cal\u00f2 LA, Cosyns E, Devuyst O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R (2017) Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 91:24\u201333","journal-title":"Kidney Int"},{"key":"2272_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0272-6386(03)00422-0","volume":"42","author":"N Kamar","year":"2003","unstructured":"Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L (2003) Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 42:184\u2013192","journal-title":"Am J Kidney Dis"},{"key":"2272_CR14","first-page":"30","volume":"110","author":"N Kamar","year":"2004","unstructured":"Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J (2004) Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 110:30\u201334","journal-title":"J Clin Virol"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcv.2007.02.006","volume":"39","author":"LN Calanca","year":"2007","unstructured":"Calanca LN, Fehr T, Jochum W, Fischer-Vetter J, M\u00fcllhaupt B, W\u00fcthrich RP, Amb\u00fchl PM (2007) Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 39:54\u201358","journal-title":"J Clin Virol"},{"key":"2272_CR16","first-page":"1","volume":"109","author":"Kidney disease: improving global outcomes (KDIGO)","year":"2008","unstructured":"Kidney disease: improving global outcomes (KDIGO) (2008) KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109:1\u201399","journal-title":"Kidney Int Suppl"},{"key":"2272_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, AI444040 Study Group (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:211\u2013221","journal-title":"N Engl J Med"},{"key":"2272_CR18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"2272_CR19","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators (2014) Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879\u20131888","journal-title":"N Engl J Med"},{"key":"2272_CR20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483\u20131493","journal-title":"N Engl J Med"},{"key":"2272_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Br\u00e4u N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"2272_CR22","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"2272_CR23","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878\u20131887","journal-title":"N Engl J Med"},{"key":"2272_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/ajg.2014.66","volume":"109","author":"AJ Muir","year":"2014","unstructured":"Muir AJ (2014) The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 109:628\u2013635","journal-title":"Am J Gastroenterol"},{"key":"2272_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/TP.0000000000001618","volume":"101","author":"M Lubetzky","year":"2017","unstructured":"Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M, Gaglio P, Akalin E, De Boccardo G (2017) Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101:1704\u20131710","journal-title":"Transplantation"},{"key":"2272_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.transproceed.2018.02.017","volume":"50","author":"A Weigert","year":"2018","unstructured":"Weigert A, Querido S, Carvalho L, Lebre L, Chagas C, Matias P, Birne R, Nascimento C, Jorge C, Adrag\u00e3o T, Bruges M, Machado D (2018) Hepatitis C virus eradication in kidney transplant recipients: a single-center experience in portugal. Transplant Proc 50:743\u2013745","journal-title":"Transplant Proc"},{"key":"2272_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66:153\u2013194","journal-title":"J Hepatol"},{"key":"2272_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"2272_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bcp.13095","volume":"83","author":"ST Pons","year":"2017","unstructured":"Pons ST, Boyer A, Lamblin G, Chennell P, Ch\u00e2tenet FT, Nicolas C, Sautou V, Abergel A (2017) Managing drug-drug inetractions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 83:269\u2013293","journal-title":"Br J Clin Pharmacol"},{"key":"2272_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/ajt.13518","volume":"16","author":"N Kamar","year":"2015","unstructured":"Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssi\u00e8re L, Esposito L, Del Bello A, M\u00e9tivier S, Barange K, Izopet J, Alric L (2015) Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 16:1474\u20131479","journal-title":"Am J Transplant"},{"key":"2272_CR31","doi-asserted-by":"publisher","first-page":"e0158431","DOI":"10.1371\/journal.pone.0158431","volume":"11","author":"MV Lin","year":"2016","unstructured":"Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV (2016) Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis c virus infection. PLoS One 11:e0158431","journal-title":"PLoS One"},{"key":"2272_CR32","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ajt.13620","volume":"16","author":"D Sawinski","year":"2016","unstructured":"Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD (2016) Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 16:1588\u20131595","journal-title":"Am J Transplant"},{"key":"2272_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12664-017-0745-5","volume":"36","author":"A Goel","year":"2017","unstructured":"Goel A, Bhadauria DS, Kaul A, Prasad N, Gupta A, Sharma RK, Rai P, Aggarwal R (2017) Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol 36:137\u2013140","journal-title":"Indian J Gastroenterol"},{"key":"2272_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/tri.12799","volume":"29","author":"S Beinhardt","year":"2016","unstructured":"Beinhardt S, Al Zoairy RA, Ferenci P, Kozbial K, Freissmuth C, Stern R, St\u00e4ttermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post-kidney transplantation setting. Transplant Int 29:999\u20131007","journal-title":"Transplant Int"},{"key":"2272_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/tri.12954","volume":"30","author":"KR Bhamidimarri","year":"2017","unstructured":"Bhamidimarri KR, Ladino M, Pedraza F, Guerra G, Mattiazzi A, Chen L, Ciancio G, Kupin W, Martin P, Burke G, Roth D (2017) Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. Transplant Int 30:865\u2013873","journal-title":"Transplant Int"},{"key":"2272_CR36","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1016\/j.transproceed.2016.09.021","volume":"48","author":"A Suarez-Benjumea","year":"2016","unstructured":"Suarez-Benjumea A, Gonzalez-Corvillo C, Sousa JM, Bernal Blanco G, Su\u00f1er Poblet M, Perez Valdivia MA, Gonzalez Roncero FM, Acevedo P, Gentil Govantez MA (2016) Hepatitis C virus in kidney transplant recipients: a problem on the path to eradication. Transplant Proc 48:2938\u20132940","journal-title":"Transplant Proc"},{"key":"2272_CR37","doi-asserted-by":"publisher","first-page":"e7568","DOI":"10.1097\/MD.0000000000007568","volume":"96","author":"K Chen","year":"2017","unstructured":"Chen K, Lu P, Song R, Zhang J, Tao R, Wang Z, Zhang W, Gu M (2017) Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: a PRISMA-compliant study. Medicine 96:e7568","journal-title":"Medicine"},{"key":"2272_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jceh.2017.06.007","volume":"7","author":"AC Anand","year":"2017","unstructured":"Anand AC, Agarwa SK, Garg HK, Khanna S, Gupta S (2017) Sofosbuvir and ribavirin for 24\u00a0weeks is an effective treatment option for recurrent hepatitis C infection after living donor liver transplantation. J Clin Exp Hepatol 7:165\u2013171","journal-title":"J Clin Exp Hepatol"},{"key":"2272_CR39","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3748\/wjg.v22.i4.1650","volume":"22","author":"S Belga","year":"2016","unstructured":"Belga S, Doucette KE (2016) Hepatitis C in non-hepatic solid organ transplant candidates and recipients: a new horizon. World J Gastroenterol 22:1650\u20131663","journal-title":"World J Gastroenterol"},{"key":"2272_CR40","unstructured":"eMedFusion. Drug interaction chart.\u00a02015. \nhttp:\/\/www.hep-druginteractions.org\/"},{"key":"2272_CR41","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/ajt.13111","volume":"15","author":"P Badri","year":"2015","unstructured":"Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, Menon R (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 15:1313\u20131322","journal-title":"Am J Transplant"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02272-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:12:04Z","timestamp":1600211524000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02272-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02272-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"12 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to compliance with ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}